The MURDOCK Study Registry and Biorepository Horizon 1.5 (MURDOCK)

February 2, 2026 updated by: Duke University

Measurement to Understand Reclassification of Disease of Cabarrus/Kannapolis The MURDOCK Study Registry and Biorepository Horizon 1.5

The MURDOCK Study Community Registry and Biorepository (Horizon 1.5) aims to create a large-scale community registry and biorepository that can be used as a vehicle for future health services, epidemiologic, clinical trials and other omics-related research.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

The MURDOCK Study Community Registry and Biorepository's activities include enrolling approximately 50,000 participants who live in Cabarrus County and/or Kannapolis, North Carolina. Participants must consent to (1) use of the data provided by the participant through completion of the Participant Registry Questionnaire for epidemiologic population characterization, (2) annual contact to update their MURDOCK Horizon 1.5 database record, (3) release of their medical information, including but not limited to demographic information, problem lists, medications, social and family history, and results of laboratory and other testing modalities from pre-existing paper or electronic health records or electronic health records that may become available in the future, (4) provision of a blood and urine sample, and (5) contact up to four times/year to request participation in additional research studies.

Study Type

Observational

Enrollment (Estimated)

50000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • North Carolina
      • Kannapolis, North Carolina, United States, 28081
        • Duke Clinical Translational Science Institute-MURDOCK Study

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The Community Registry and Biorepository is designed to create a community registry and biorepository populated by approximately 50,000 residents of Cabarrus County and/or the city of Kannapolis in North Carolina.

Description

Inclusion Criteria:

  1. A resident of Cabarrus County and/or the city of Kannapolis (and surrounding regions) for 6 or more months of the year
  2. At least 18 years of age
  3. Able to understand and give written informed consent, or have a legal guardian or caregiver present to give informed consent by proxy (assent from a participant between ages 12-18 will be obtained when their parent or legal guardian consents on their behalf).
  4. Willing and able to participate in all 5 components of the registry and biorepository as described above in Section III

Exclusion Criteria:

1. There are no exclusions to participation if all inclusion criteria have been met.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
community
Genetic: Biomarker studies

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The MURDOCK Study Registry and Biorepository Horizon 1.5
Time Frame: Upto 119 months
To provide information for large-scale epidemiologic and clinical translational research and the research infrastructure to identify specific phenotypes and outcomes to improve medicine
Upto 119 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Duke University

Investigators

  • Principal Investigator: Kristin M Newby, MD, Duke University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2009

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

October 15, 2012

First Submitted That Met QC Criteria

October 16, 2012

First Posted (Estimated)

October 17, 2012

Study Record Updates

Last Update Posted (Actual)

February 4, 2026

Last Update Submitted That Met QC Criteria

February 2, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Pro00011196

Drug and device information, study documents

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Disease

Clinical Trials on Biomarker studies

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe